Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Jaffetilchin Investment Partners LLC

Jaffetilchin Investment Partners LLC lowered its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.6% during the third quarter, Holdings Channel.com reports. The institutional investor owned 7,859 shares of the medical equipment provider’s stock after selling 127 shares during the period. Jaffetilchin Investment Partners LLC’s holdings in Intuitive Surgical were worth $3,861,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ISRG. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical during the second quarter valued at $26,000. Godsey & Gibb Inc. boosted its stake in shares of Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the last quarter. Creekmur Asset Management LLC grew its holdings in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares in the last quarter. LGT Financial Advisors LLC boosted its position in Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC raised its holdings in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Up 1.0 %

ISRG opened at $542.00 on Monday. Intuitive Surgical, Inc. has a twelve month low of $281.12 and a twelve month high of $542.00. The firm has a market cap of $193.05 billion, a price-to-earnings ratio of 86.25, a PEG ratio of 5.27 and a beta of 1.39. The company has a fifty day simple moving average of $493.92 and a 200 day simple moving average of $452.79.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Royal Bank of Canada raised their price target on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Morgan Stanley boosted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. BTIG Research set a $535.00 price target on shares of Intuitive Surgical in a report on Friday, October 18th. JPMorgan Chase & Co. lifted their target price on Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Truist Financial lifted their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,655,048.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Desantis sold 188 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $482.21, for a total value of $90,655.48. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,655,048.26. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,006 shares of company stock worth $33,727,766 in the last 90 days. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.